Compare BSET & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BSET | SABS |
|---|---|---|
| Founded | 1902 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.2M | 181.4M |
| IPO Year | 1987 | N/A |
| Metric | BSET | SABS |
|---|---|---|
| Price | $16.21 | $3.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.80 |
| AVG Volume (30 Days) | 20.1K | ★ 298.5K |
| Earning Date | 01-28-2026 | 11-13-2025 |
| Dividend Yield | ★ 4.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $330,953,000.00 | $114,698.00 |
| Revenue This Year | $3.11 | N/A |
| Revenue Next Year | $3.00 | N/A |
| P/E Ratio | $18.29 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.62 | $1.00 |
| 52 Week High | $19.75 | $6.60 |
| Indicator | BSET | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 47.47 | 55.89 |
| Support Level | $15.97 | $3.56 |
| Resistance Level | $16.64 | $3.83 |
| Average True Range (ATR) | 0.44 | 0.21 |
| MACD | -0.18 | -0.02 |
| Stochastic Oscillator | 22.86 | 57.73 |
Bassett Furniture Industries Inc is a manufacturer, marketer, and retailer of home furnishings products in the United States. It operates through the following segments: The Wholesale segment focuses on the design, manufacture, sourcing, sale, and distribution of furniture products, the Retail segment which consists of company-owned stores, and the Corporate and others segment. Majority of revenue is from Wholesale sales of furniture and accessories.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.